

Supplementary Table 1. Second and third line bDMARD Persistence

	N	Median (months)	[95%CI]
Second Line bDMARD Persistence:			
Adalimumab	359	15	[13, 20]
Golimumab	218	34	[23, 48]
Infliximab	43	21	[13, 48]
Secukinumab	75	20	[9, not yet reached]
Other	73	12	[9, 19]
Third Line bDMARD Persistence*:			
Adalimumab	53	15	[8, 20]
Golimumab	112	26	[14, 40]
Secukinumab	110	10	[6, 15]
Certolizumab-pegol	53	10	[7, 22]

[bDMARD; biologic disease modifying antirheumatic drug, CI; confidence interval]

*Only included bDMARDs with patient numbers > n = 10 for third line persistence

The Journal of Rheumatology

Supplementary Table 2. Demographics for the total first line treated population and the etanercept and adalimumab first line treated populations pre- and post-2012

	Overall treated population		Etanercept and adalimumab treated population only	
	Pre-2012	Post-2012	Pre-2012	Post-2012
N	483	2040	394	1430
Age (years)				
mean (SD)	44.6 (12.9)	44.1 (14.0)	44.2 (12.7)	44.3 (13.7)
median	45.0	43.0	44.0	44.0
IQR	35, 53	33, 54	35, 52	33, 54
Age (years), n (% of column)				
18 – 34	115 (23.8%)	574 (28.1%)	97 (24.6%)	389 (27.2%)
35 – 44	124 (25.7%)	521 (25.5%)	104 (26.4%)	367 (25.7%)
45 – 54	141 (29.2%)	455 (22.3%)	118 (29.9%)	330 (23.1%)
55 – 64	64 (13.3%)	304 (14.9%)	44 (11.2%)	220 (15.4%)
65 – 74	32 (6.6%)	153 (7.5%)	25 (6.3%)	104 (7.3%)
75+	7 (1.4%)	33 (1.6%)	6 (1.5%)	20 (1.4%)
Gender, n (% of column)				
Male	354 (73.3%)	1118 (54.8%)	296 (75.1%)	799 (55.9%)
Female	129 (26.7%)	904 (44.3%)	98 (24.9%)	617 (43.1%)
Unassigned	0 (1.0%)	18 (0.9%)	0 (0.0%)	14 (0.9%)
Time from onset (months), median IQR	69.6 (7.2, 182.5) [n = 402]	16.1 (2.1, 86.3) [n = 1857]	78.5 (8.7, 183.0) [n = 394]	16.2 (3.0, 86.2) [n = 1312]
CRP (mg/L), median IQR	5.0 (3.0, 12.0) [n = 245]	5.0 (2.0, 11.0) [n = 1782]	4.0 (1.6, 9.0) [n = 154]	4.0 (1.8, 9.0) [n = 931]
ESR (mm/hr), median IQR	7.0 (5.0, 15.0) [n = 239]	8.0 (5.0, 18.0) [n = 1768]	6.0 (4.0, 14.0) [n = 152]	7.0 (4.0, 15.0) [n = 927]
Baseline treatment combinations, n (%)				
NSAIDs	203 (42.0%)	1220 (59.8%)	163 (41.4%)	896 (62.7%)
cDMARDs	93 (19.3%)	510 (25.0%)	68 (17.3%)	337 (23.6%)
Corticosteroids	113 (23.4%)	776 (38.0%)	97 (24.6%)	540 (37.8%)

[bDMARD; biologic disease modifying antirheumatic drugs, BASDAI; Bath Ankylosing Spondylitis Disease Activity Index, cDMARDs; conventional disease modifying antirheumatic drugs, CRP; C-reactive protein, ESR; erythrocyte sedimentation rate, IQR; interquartile range, NSAIDs; nonsteroidal anti-inflammatory drugs, SD; standard deviation]